CBIO

Crescent Biopharma
CBIO

Overview Fund Trends Analyst Outlook Journalist POV

36 hedge funds and large institutions have $3M invested in Crescent Biopharma in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more funds holding

Funds holding: →

less ownership

Funds ownership: →

less capital invested

Capital invested by funds: $ → $

67% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 12

Holders
36
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$23.7K
2
+$16.9K
3
+$14K
4
Two Sigma Investments
Two Sigma Investments
New York
+$7.54K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$5.75K

Top Sellers

1
-$2.42M
2
-$227K
3
-$29.3K
4
Millennium Management
Millennium Management
New York
-$28.2K
5
SIG
Sargent Investment Group
Maryland
-$28.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
1
$1.61M
2
$451K
3
$332K
4
$132K
5
$123K
6
$88.1K
7
$59K
8
$42.1K
9
$30.3K
10
$19.8K
11
$16.9K
12
$14K
13
$11.6K
14
$7.77K
15
$7.72K
16
$7.54K
17
$6.48K
18
$6.42K
19
$5.19K
20
$5K
21
$4.21K
22
$3.75K
23
$3.19K
24
$3K
25
$2.54K
1
2